Nosipho Ngubane

Medicine · Health Sciences

10h-index2.4kcitations12works21.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(11), Infectious Diseases and Tuberculosis(4), Diagnosis and treatment of tuberculosis(3), HIV/AIDS drug development and treatment(2), Pneumonia and Respiratory Infections(2)

Publications11 total

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial
The Lancet Respiratory Medicine·2024· 10 citedOpen Access
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
The Lancet Infectious Diseases·2024· 48 citedOpen Access
Radiographic characteristics of rifampicin-resistant tuberculosis in the STREAM stage 1 trial and their influence on time to culture conversion in the short regimen
BMC Infectious Diseases·2024· 2 citedOpen Access
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
New England Journal of Medicine·2022· 318 citedOpen Access
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
The Lancet·2022· 134 citedOpen Access
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
New England Journal of Medicine·2022· 511 citedOpen Access
Effectiveness of GenoType MTBDR <i>sl</i> in excluding TB drug resistance in a clinical trial
The International Journal of Tuberculosis and Lung Disease·2021· 3 citedOpen Access
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
The International Journal of Tuberculosis and Lung Disease·2021· 30 citedOpen Access
Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
BMJ Open·2020· 15 citedOpen Access
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
New England Journal of Medicine·2020· 964 citedOpen Access
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
New England Journal of Medicine·2019· 389 citedOpen Access

Frequent Co-authors

Francesca Conradie(8), Ronelle Moodliar(7), Melvin Spigelman(5), Andrew Nunn(5), Sarah Meredith(5), Bazarragchaa Tsogt(5), Mohammed Rassool(5), Pauline Howell(4), Angela M. Crook(4), Timothy D. McHugh(4), Morounfolu Olugbosi(4), Chen‐Yuan Chiang(4), Armand Van Deun(4), Daniel Meressa(4), Gabriela Torrea(4), I. D. Rusen(4), Daniel E. Everitt(3), Carl M. Mendel(3), Juliano Timm(3), Genevieve H. Wills(3)